Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Liu

Showing results (421-430 of 574) with videos related to

Pageof 58
Sort By:
Molecular Therapy. Nucleic Acids|December 24, 2025
mRNA-LNP vaccination orchestrates systemic immunity to control human papillomavirus-positive head and neck squamous cell carcinomaKe Qiu, Minzi Mao, Yao Song, et al.
Genetic Epidemiology|February 4, 2015
Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancerJulia G Poirier, Paul Brennan, James D McKay, et al.
Cancer Treatment and Research Communications|March 12, 2022
Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare systemKirstin Perdrizet, Tracy L Stockley, Jennifer H Law, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2024
Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-NephrologyAbhijat Kitchlu, Verônica T Costa E Silva, Shuchi Anand, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Cancers|July 2, 2021
A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted AnalysisMichael Yan, Samantha Sigurdson, Noah Greifer, et al.
Carcinogenesis|January 17, 2013
Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma riskJennifer R Wang, Sarah J B Gramling, David P Goldstein, et al.
The European Respiratory Journal|January 24, 2015
Plasma pro-surfactant protein B and lung function decline in smokersJanice M Leung, John Mayo, Wan Tan, et al.
Pageof 58

Showing results (421-430 of 574) with videos related to

Sort By:
Pageof 58
Molecular Therapy. Nucleic Acids|December 24, 2025
mRNA-LNP vaccination orchestrates systemic immunity to control human papillomavirus-positive head and neck squamous cell carcinomaKe Qiu, Minzi Mao, Yao Song, et al.
Genetic Epidemiology|February 4, 2015
Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancerJulia G Poirier, Paul Brennan, James D McKay, et al.
Cancer Treatment and Research Communications|March 12, 2022
Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare systemKirstin Perdrizet, Tracy L Stockley, Jennifer H Law, et al.
Clinical Journal of the American Society of Nephrology : CJASN|June 7, 2024
Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-NephrologyAbhijat Kitchlu, Verônica T Costa E Silva, Shuchi Anand, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Cancers|July 2, 2021
A Comparison of Hypofractionated and Twice-Daily Thoracic Irradiation in Limited-Stage Small-Cell Lung Cancer: An Overlap-Weighted AnalysisMichael Yan, Samantha Sigurdson, Noah Greifer, et al.
Carcinogenesis|January 17, 2013
Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma riskJennifer R Wang, Sarah J B Gramling, David P Goldstein, et al.
The European Respiratory Journal|January 24, 2015
Plasma pro-surfactant protein B and lung function decline in smokersJanice M Leung, John Mayo, Wan Tan, et al.
Pageof 58